Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Fundamentals of Pathological Processes > FPP-Week 2 > Flashcards

FPP-Week 2 Flashcards

1
Q

Benign vs Malignant Tumors

A

Benign: “-oma”, resemble normal tissue, slow growth, encapsulated
Malignant: “carcinoma or sarcoma”, can look very different, variable growth rate, invasive, metastasize

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Types of cell origin on Tumors

A

Epithelial: endo/ectoderm, adenoma or adenoCARCINOMA
Mesenchymal: mesoderm, lipoma or lipoSARCOMA
Hematolymphoid: always malignant, leukemias, lymphomas
Melanocytes: neural crest, nevus (mole) or melanoma
[[Teratomas: multiple germ layers]]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Tumor-like conditions

A

Hamartoma: mass or disorganized mature tissue (developmental issue)
Choriostoma: ectopic tissue in wrong location

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Dysplasia

A

Disordered growth of epithelium
histologic dx
severe= carcinoma in situ (doesn’t extend past basement membrane)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Metastasis

A

criteria for malignancy
Basal cell carcinoma and gliomas do NOT metastasize
Hematogenous (via veins)- common for sarcomas, usually to liver, lung, vertebre
Lymphatics: common for carcinomas, sentinel nodes
Seeding body cavities: usually peritoneal,, ovarian cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Tumor Stage

A

TMN system
tumor size
nodal involvement
metastasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

CAR-modified T cells

A

fusion protein of tumor-specific antibody with co-stimulatory factors on T-cells, so when antibody binds tumor cell, the T-cell activates and kills the tumor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

HER2/Neu (ERB B2)

A

Oncogene
abnormal constitutive activation (usually overexpression)
growth factor receptor-> tyrosine kinase
amplification in breast CA, poor prognosis, predicts estrogen therapy failure
Trastuzumab= antibody against HER2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

c-KIT

A

oncogene
growth factor receptor-> tyrosine kinase
point mutation in GISTs (gastro intestinal stromal tumors)
Imatinib mesylate= tyrosine kinase inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

RAS

A

oncogene family
Point mutations, 15-20% of all tumors, most common
K-RAS= colon CA
also pancreas and lung
GTP-binding proteins with reduced GTPase activity, which keeps them in active form (downstream of growth factor receptors)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

c-ABL

A

Oncogene
translocation (9,22), Philadelphia chromosome, makes bcr-abl fusion-> constitutively active-> tyrosine kinase activity
CML- Chronic Myelogneous Leukemia
and ALL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MYC

A

Oncogene
transcription factor, activates genes
C-MYC= continued expression (Burkitt Lymphoma)
N-MYC= amplification (neuroblastoma)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Cyclin D1

A

Oncogene
cell-cycle regulator
activates CDK4 which phosphorylates Rb, which G1->S
translocation (11,14), Cyclin D1-IgH fusion, overexpression
Mantle Cell Lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

p53

A

Oncogene
Causes cell cycle arrest and initiation of apoptosis
“first hit”= inherited, “second hit”= acquired
Li-Fraumeni Syndrome= inherited mutated p53= higher risk of cancers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Rb

A

Oncogene
encodes tumor suppressor protein, cell-cycle regulator
mutations cause uncontrolled E2F activation-> cell growth
Retinoblastoma and osteosarcoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Familial Adenomatous Polyposis (FAP)

A

1000s of mucosal polyps in colon
potential to transform into cancer
Mutation of APC gene on chromosome 5q21
-> B-catenin accumulation (2-hits reqd)

17
Q

BAX

A

oncogene

Pro-apoptotic

18
Q

BCL-2

A 
oncogene
Anti-apoptotic
overexpressed in many lymphomas
translocation (14;18): IgH-bcl2 fusion= 
Follicular Lymphoma
19
Q

SIS

A

Oncogene

overexpression-> astrocytoma, osteosarcoma

20
Q

Carcinogens

A

Alkylating agents (electrophilic)
polycyclic aromatic hydrocarbons (need to be P450 activated, can have inducible form)
UV and ionizing radiation
Microbes (many)

21
Q

Oncogenic Microbes

A

Viral genome integration:
-HPV, EBV, HepB
Burkitt Lymphoma= EBV
Stimulation of inflammatory response and regeneration:
-HepB,C, H pylori
H pylori= gastric adenocarcinoma and MALTomas

22
Q

Regular vs Tumor angiogenesis

A

Regular: hypoxia->up VEGF,FGF,MMP->budding growth of capillaries->then down VEGF, up PDGF, Ang, TGFb
Tumor: hypoxia->up VEGF, PDGF->macrophages->EGF, MMP9, VEGF->disrupt ECM->budding of new capillaries->more VEGF, no resolution->weak, leaky, disorganized vessels
Also loosely attached pericytes and gaps in capillaries, fewer lymphatics, higher pressure

23
Q

Angiogenic switch

A

The change that allows hyperplastic cells to transform into tumors
signals->mast cells and macrophages->MMP-9->disrupt ECM, release bound VEGF->make blood vessels
more vessels/VEGF=more aggressive tumor

24
Q

Angiogenesis activators/inhibitors

A

activators: VEGF (makes leaky vessels, target of most therapy), FGF, PDGF
inhibitors: thrombospondin, angiostatin, endostatin

25
Q

HIF-1

A

hypoxia sensor
normoxia->bound to VHL and degraded
hypoxia-> activates genes (VEGF)
VHL disease-> constitutively actives hypoxia genes (tumor risk)

26
Q

Log-Kill

A

constant dose kills a constant fraction of tumor cells
need log-kill of 2-4 to be effective, and need 4-12 cycles
Need to balance frequency to allow normal cells to recover but not the tumor cells

27
Q

Class I cancer drugs: Cell-cycle non-specific

A

alkylating agents, non-specific cytotoxiticy
Mechlorethamine
Carmustine

28
Q

Class II cancer drugs: cell-cycle specific

A 
Target a specific phase of cell cycle
Frequent dosing
G1: Prednisone
S: Cytarabine, fluorouracil, Methotrexate, Mercaptopurine, Hydroxyurea
G2: Bleomycin, Etoposide, Paclitaxel
M: Vinblastine, Vincristine
29
Q

Class III cancer drugs: cell-cycle specific, phase non-specific

A 
Cytotoxic to all but G0
Single large doses
Alkylating agent: cyclophosphamide
Misc: Cisplatin
Antibiotic: Doxorubicin
30
Q

Lynch Syndrome (HNPCC)

A

Mutation in MLH1, MSH2, MSH6, PMS2, or EPCAM genes
Increases risk of colorectal and other cancers
Mismatch repair gene defects lead to microsatellite instability (nucleotide repeats)
Path: lymphocytic infiltrate, Crohn’s rxn, Mucinous, Signet ring, Medullary pattern
Microsatellite instability also caused by somatic mutation in BRAF->hypermethylation of MLH1

31
Q

Factor 5 Leiden

A

most common inherited predisposition for thrombosis

mutation in protein C (which is anti-coagulant, cleaves factor V, VIII)

32
Q

Antiphospholipid antibodies

A

acquired autoantibodies against PL complexes

increases thromboses

33
Q

Shock

A 
systemic hypoperfusion
hypovolemic
cardiogenic
septic (warm, flushed,, gram+ bacteria)
neurogenic
anaphylactic (IgE)

Fundamentals of Pathological Processes (3 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions